Article Text

PDF
Hypothyroid ataxia complicating monoclonal antibody therapy
  1. Abdul Badran1,
  2. Carla Moran2,
  3. Alasdair J Coles3
  1. 1University of Cambridge, Churchill College, Cambridge, UK
  2. 2Wellcome-MRC Institute of Metabolic Science, University of Cambridge, Cambridge, UK
  3. 3Department of Clinical Neurosciences, Addenbrooke’s Hospital, University of Cambridge, Cambridge, UK
  1. Correspondence to Abdul Badran, University of Cambridge, Churchill College, Storey’s Way, Cambridge, CB3 0DS, UK; arb94{at}cam.ac.uk

Abstract

We present a case of cerebellar dysfunction due to severe hypothyroidism induced by pembrolizumab, a member of the ‘immune checkpoint inhibitor’ class of cancer immunotherapies. Thyroxine replacement completely resolved his symptoms and signs. We also discuss the neurological immune-related complications of checkpoint inhibitors.

  • neuroimmunology
  • cerebellar ataxia
  • neuroendocrinology

Statistics from Altmetric.com

Footnotes

  • Contributors AB drafted this case report. CM and AJC edited the report and contributed to the discussion.

  • Competing interests None declared.

  • Patient consent Obtained.

  • Provenance and peer review Not commissioned; externally peer reviewed. This paper was reviewed by Marios Hadjivassiliou, Sheffield, UK.

  • Correction notice This article has been corrected since it was published Online First. The affiliations numbered 2 and 3 have been switched around.

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.